Salute e Benessere

Correction: Notice of Annual General Meeting of Orexo

Participation, etc. Participation, etc. Shareholders who wish to participate in the meeting must be recorded in the share register maintained by Euroclear Sweden AB on Thursday18 April 2024, and notify Orexo of their intention to attend the meeting not later than on Monday22 April 2024by post to Orexo AB, P.O. Box 303, SE-751 05 Uppsala,Sweden, by telephone +46 (0) 18 780 88 00, by telefax +46 (0) 18 780 88 88, or by e-mail tolena.wange@orexo.com The notification shall...
PR Newswire
22/03/2024

Philips convenes the Annual General Meeting of Shareholders 2024

Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), today announced it has convened the Annual General Meeting of Shareholders (AGM) 2024 and published the agenda with explanatory notes. As previously announced, the agenda includes:Proposals to re-appoint Chairman Feike Sijbesma (Dutch, 1959) and Peter Löscher (Austrian, 1957) as members of the Supervisory Board, with effect from May 7, 2024.Proposal to appoint Charlotte Hanneman (Dutch, 1978) as member of the...
Nasdaq GlobeNewswire
22/03/2024

Dedicares Annual and Sustainability Report 2023 is now available on the website

This information is mandatory for Dedicare AB (publ) to publish pursuant to the Swedish Securities Markets Act. This information was submitted for publication through the agency of the below contact at 8 a.m. CET on 22 March 2024. This information is mandatory for Dedicare AB (publ) to publish pursuant to the Swedish Securities Markets Act. This information was submitted for publication through the agency of the below contact at8 a.m. CETon22 March 2024. For more information,...
PR Newswire
22/03/2024

Press Release: Availability of the Q1 2024 Memorandum for modelling purposes

Availability of the Q1 2024 Memorandum for modelling purposesParis, France – March 22, 2024. Sanofi announced today that its Q1 2024 Memorandum for modelling purposes is available on the "Investors" page of the company's website:First quarter 2024 results (sanofi.com)As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as...
Nasdaq GlobeNewswire
22/03/2024

Nicox's Shareholder Letter

Dear Shareholder,The upcoming Extraordinary General Meeting, which will take place on April 10, is of particular importance for Nicox. I am writing to you today, in my capacity as the new Chief Executive Officer, in order to share the latest information with you and request your participation in this meeting, as your support is essential to provide the Company with new momentum. It is an honor to have the trust of the Board of Directors in appointing me CEO of Nicox. Many of you know me...
Nasdaq GlobeNewswire
22/03/2024

Idorsia thanks Guy Braunstein for his years of service as he retires

Guy Braunstein, currently Chief Medical Officer and member of the Idorsia Executive Committee, to retire at the end of March 2024Allschwil, Switzerland – March 22, 2024Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development and member of the Idorsia Executive Committee since the creation of Idorsia will retire at the end of March 2024. Guy will continue to support Idorsia as an advisor,...
Nasdaq GlobeNewswire
22/03/2024

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of…

NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the USAarhus, Denmark, 22 March 2024– NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, today announces that it has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to initiate a Phase 2b...
Nasdaq GlobeNewswire
22/03/2024

UCB Convening Notice to the General Meeting of the Shareholders 2024

CONVENING NOTICE TO THE GENERAL MEETING OF SHAREHOLDERS The Board of Directors invites the shareholders for the ordinary and extraordinary general meeting of the shareholders (the “ General Meeting ” or the “ GM ”) which will be held onThursday, 25 April 2024, at 11:00 am CEST, at the registered office of UCB SA/NV, Allée de la Recherche 60 - 1070 Brussels, for the purpose of considering and voting on the items shown on the agenda set out below.Applicable participation formalities are...
Nasdaq GlobeNewswire
22/03/2024

Global Real Estate Leaders Prioritize Health to Drive Value, Improve ESG…

NEW YORK, March 22, 2024 /PRNewswire/ -- Fitwel, the world's leading certification system committed to building health for all, proudly announced the winners of the 2024 Best in Building Health Awards today. This prestigious annual recognition honors the most innovative real estate companies and individuals setting the standard for health and wellbeing in the built environment across the globe, leveraging the trusted Fitwel Standard to enhance quality of life and drive value through design and…
PR Newswire
22/03/2024

Self Esteem Brands Announces Expansion of Anytime Fitness Brand into United Arab…

"Being a long-time member of Anytime Fitness and having used the clubs around the world makes this investment a natural for me," Mobius said. "Being a long-time member of Anytime Fitness and having used the clubs around the world makes this investment a natural for me," Mobius said. Dr. Mobius is joined by fellow investorJohn Ninia, along withBen Matuteand Richmond Sy, two longtime Anytime Fitness Philippines franchise operators who will relocate toDubaiand co-invest with…
PR Newswire
22/03/2024

DNA Sequencing Market Projected to Reach $210.34 billion by 2030 - Exclusive…

DNA sequencing, a pivotal laboratory process that determines the order of nucleotides in DNA, has become crucial in diagnosing and treating diseases, medical research, and forensic studies. The technique, which translates the vital biological information encoded within DNA, is essential for understanding cellular development and functionality. Its application spans identifying genetic mutations linked to disorders and facilitating personalized medicine, addressing the increasing prevalence of…
PR Newswire
22/03/2024

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

As a result of this further delay in filing the Required Annual Filings, the Company anticipates it will not be in a position to file its interim financial statements for the three months ended January 31, 2024, its management's discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the "Required Interim Filings"). Under National Instrument 51-102, the Required Interim Filings are required to be made not later…
PR Newswire
21/03/2024

SkinPen® Precision Wins Prestigious Aesthetics Awards 2024 for "Best Energy…

"We are incredibly proud to receive this esteemed recognition," said Andy Moulton, Vice President of International Sales for Crown Aesthetics. "This award is a testament to our unwavering commitment to innovation and excellence in healthcare. SkinPen Precision embodies our dedication to improving patient outcomes, and we are honored to see its impact acknowledged on such a significant platform." "We are incredibly proud to receive this esteemed recognition,"…
PR Newswire
21/03/2024

Information on the Total Number of Voting Rights (Denominator) following…

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas Atlas Special Opportunities, LLC has converted 6 convertible bonds in Oxurion resulting in a EUR 150,000 capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion...
Nasdaq GlobeNewswire
21/03/2024

ONWARD® Medical Publishes Prospectus for Listing of New Shares

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, March21, 2024(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
21/03/2024

Zealand Pharma major shareholder announcement: Van Herk Investments

Company announcement – No. 18 / 2024 Zealand Pharma major shareholder announcement: Van Herk InvestmentsCopenhagen, Denmark, 21 March 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the receipt on 21 March 2024 of notification pursuant to Section 38 of the Danish Capital Markets Act from the following major shareholders:As...
Nasdaq GlobeNewswire
21/03/2024

Awiqli® (once-weekly basal insulin icodec) recommended for approval for the…

Bagsværd, Denmark, 21 March 2024– Novo Nordisk today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorisation for Awiqli ®(the brand name for once-weekly basal insulin icodec) for treatment of diabetes in adults. The positive CHMP opinion is based on results from the ONWARDS phase 3a clinical trial programme. Once-weekly basal insulin icodec achieved superior blood sugar...
Nasdaq GlobeNewswire
21/03/2024

Essity's 2024 Annual General Meeting

The Meeting resolved in accordance with the Board of Director's proposal and decided on a dividend of SEK 7.75 per share for the 2023 fiscal year. Record date for the dividend is set to Monday, March 25, 2024. The dividend is scheduled to be distributed by Euroclear Sweden AB on Thursday, March 28, 2024. The Meeting resolved in accordance with the Board of Director's proposal and decided on a dividend ofSEK 7.75per share for the 2023 fiscal year. Record date for the dividend is set to...
PR Newswire
21/03/2024

NTG Nordic Transport Group A/S - Annual General Meeting 2024

Company announcement no. 4 - 2421 March 2024 NTG Nordic Transport Group A/S - Annual General Meeting 2024Today, at 14:00, NTG Nordic Transport Group A/S (“NTG” or the “Company”), CVR no. 12 54 61 06, held its Annual General Meeting at Glostrup Park Hotel, Hovedvejen 41, 2600 Glostrup, Denmark.All proposals presented to the General Meeting were adopted: Items 1-3The General Meeting acknowledged the management's report on NTG's activities in the past financial year and NTG's...
Nasdaq GlobeNewswire
21/03/2024

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 21 March 2024 -Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “We are very pleased with the performance in 2023 which was an exceptional year of innovation, growth, value creation and impact for Novo Nordisk. Globally, we reached more than 40 million patients, more patients than at any point in our 100-year history. As we strive to keep pace with demand, we have invested...
Nasdaq GlobeNewswire
21/03/2024

Sandoz opens new antibiotic production facility in Austria, to significantly…

MEDIA RELEASE EUR 50m investment in Kundl plant extension emphasizes commitment to serve more patients with critical antibiotics, produced entirely in EuropeAdditional manufacturing area of 3,000m 2means Kundl can now manufacture 240 million packages per yearRepresents capacity increase of 20% over 2023 and more than doubling from 2021 output levelsAutomation and innovative technologies allow production of one billion more penicillin tablets and doubling of output for key pediatric...
Nasdaq GlobeNewswire
21/03/2024

OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive…

-Phase 2 OK-101 efficacy data to be released March 22nd, 2024--KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March21, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases including neuropathic corneal pain (NCP), an ocular condition associated...
Nasdaq GlobeNewswire
21/03/2024

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 21, 2024– Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Tuesday, 16 April 2024, at 4 PM CEST at Comwell Borupgaard, Nørrevej 80, DK-3070 Snekkersten, Denmark with the following agenda: The Board of Directors' report on the Company's activities in the past year.Presentation of the Annual Report for adoption.A proposal from the Board of...
Nasdaq GlobeNewswire
21/03/2024

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Interim clinical data update on ACTengine® IMA203 GEN1 (PRAME) in melanoma at RP2D in November 2023: 50% confirmed objective response rate with median duration of response not reached at median follow-up of 14.4 months; IMA203 was well toleratedRegistration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024First clinical data updates for Immatics' next-generation...
Nasdaq GlobeNewswire
21/03/2024
Altri  Comunicati